Prostate-specific antigen: A cancer fighter and a valuable messenger

Clinical Chemistry

Volumn 46, Issue 7, 2000, Pages 896-900

  Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; DISEASE MARKER; METASTASIS; PATHOGENESIS; PROSTATE CANCER; SHORT SURVEY; TUMOR GROWTH;

EID: 0033927113     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.7.896     Document Type: Short Survey

References (44)

1. 1. Diamandis EP. Prostate-specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-6.
2. 2. Diamandis EP, Yu H. New biological functions of prostate specific antigen? J Clin Endocrinol Metab 1995;80:1515-7.
3. 3. Lianidou ES, Angelopoulou K, Katsaros D, Durando A, Massobrio M, Diamandis EP. Fragment analysis of the p53 gene in ovarian tumors. Clin Biochem 1998;31:551-3.
4. 4. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
5. 5. Yousef GM, Luo LY, Diamandis EP. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res 1999;19:2843-52.
6. 6. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, WangTJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45: 729-44.
7. 7. Diamandis EP, Yousef GM, Luo LY, Magklara M, Obiezu CV. The new human kallikrein gene family - implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
8. 8. Stenman UH. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 1999;45:753-4.
9. 9. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci U S A 1999;96:3114-9.
10. 10. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in the prostate and breast tissues and is hormonally regulated. Cancer Res 1999;59:4252-6.
11. 11. Stephenson SA, Verity K, Ashworth LK, Clements JA. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expended human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999;274: 23210-4.
12. 12. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:902-23.
13. 13. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.
14. 14. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
15. 15. Arcangeli CG, Humphrey PA, Smith DS, Harmon TJ, Shepherd DL, Keetch DW, Catalona WJ. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998;51:558-64.
16. 16. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RD, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
17. 17. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
18. 18. Lilja H. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Investig 1987;80:281-5.
19. 19. Fichtner J, Graves HC, Thatcher K, Yemoto C, Shortliffe LM. Prostate specific antigen releases a kinin-like substance on proteolysis of seminal vesicle fluid that stimulates smooth muscle contraction. J Urol 1996;155:738-42.
20. 20. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996;56: 3371-9.
21. 21. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998;58:4782-6.
22. 22. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2:624-36.
23. 23. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, et al. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 1991;49:645-9.
24. 24. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, et al. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomark Prev 1996;5:967-70.
25. 25. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, et al. Prostate specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995;55:2104-10.
26. 26. Yu H, Levesque MS, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer. A large United States cohort study. Clin Cancer Res 1998;4:1489-97.
27. 27. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996;40:171-8.
28. 28. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP. Decreased concentration of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hk2) in malignant versus non-malignant prostatic tissue. Urology 2000:in press.
29. 29. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate specific antigen in endovcrine-treated prostate carcinomas. Clin Cancer Res 2000;6: 160-5.
30. 30. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91: 1635-40.
31. 31. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999;81: 1269-73.
32. 32. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, et al. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 1999;79:888-94.
33. 33. Diamandis EP, Helle SJ, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999;85:891-8.
34. 34. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995;1:1089-94.
35. 35. Cohen P, Graves HCB, Peehl DM, Kamarei M, Guidice LC, Rosenfeld RG. Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1991;73:401-7.
36. 36. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998;17:383-90.
37. 37. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, et al. Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 1999;91:1663-9.
38. 38. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptor. Biochem Biophys Res Commun 1993;192: 940-7.
39. 39. Iwamura M, Hellman J, Cockett ATK, Lilha H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996;48:317-25.
40. 40. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996;156:526-31.
41. 41. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41:1567-73.
42. 42. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-4.
43. 43. Lai LC, Erbas H, Lennard TWJ, Peaston RT. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 1996; 66:743-6.
44. 44. Balbay MD, Juang P, Ilansa N, Williams S, McConkey D, Fidler JJ, et al. Stable transfection of human prostate cancer cell line PC-3 with prostate specific antigen induces apoptosis both in-vivo and in-vitro [Abstract]. Proc Am Assoc Cancer Res 1999;40:225-6.